Novel Drug May Help Repair Failing Hearts
Cimaglermin, a new experimental drug, may help restore cardiac function after heart failure, according to a first-in-man study published today in JACC: Basic to Translational Science.
Heart failure, characterized by a loss of cardiac function, is among the leading causes of death worldwide. A significant portion of heart failure patients, particularly those with severe left ventricular systolic dysfunction, do not sufficiently respond to current medical therapy.
Researchers examined the safety and efficacy of a single infusion of cimaglermin, which acts as a growth factor for the heart, helping the structural, metabolic and contractile elements of the heart to repair itself following injury. The study enrolled 40 heart failure patients who were taking optimal medical therapy for at least three months prior to the trial. Compared to patients who received a placebo, patients who received a high dose of cimaglermin had a sustained increase in left ventricular ejection fraction, or pumping capacity, through 90 days after dosing, with the maximum increase reached at day 28.
“These findings support continued clinical development of the investigational drug cimaglermin, including further safety evaluations and detailing the potential improvement on clinical heart failure outcome measures,” said Daniel J. Lenihan MD, from the division of cardiovascular medicine at Vanderbilt University and the lead author of the study. “As with all experimental therapeutics, additional studies will be required and subject to regulatory review to determine if the relative risks and benefits of cimaglermin warrant approval.”
The most common side effects were headache and nausea, which were temporarily associated with exposure to the drug. One patient receiving the highest planned dose of cimaglermin experienced an adverse reaction that met the stopping criteria of Federal Drug Administration guidance for drug induced liver injury.
Limitations of this study include the small sample size and the fact that patients only received a single infusion rather than multiple doses.
“Although the results of the study must be regarded as provisional because of the small numbers of patients, the results of this study are nonetheless very exciting,” said Douglas L. Mann, MD, FACC, editor-in-chief of JACC: Basic to Translational Science. “Instead of blocking the fundamental mechanisms that lead to cardiac injury, the early results with cimaglermin suggest that it may also be possible to administer therapeutics that allow the failing heart to repair itself using its own repair mechanisms. If the results of this study can be replicated and translated into improvements in clinical outcomes in larger numbers of patients in phase II and III clinical trials, it will represent a paradigm shift in the way in which clinicians treat patients with heart failure.”
Learn more: Novel Drug May Help Repair Failing Hearts
Receive an email update when we add a new HEART FAILURE article.
The Latest on: Restore cardiac function
via Google News
The Latest on: Restore cardiac function
- In an Astounding New Book, a Neuroscientist Reveals the Profound and Science-Backed Benefits Art Has on Our Healthon March 2, 2021 at 5:42 am
A new book out in French, "L'art qui guérit" by neuroscientist Pierre Lemarquis details how art can heal the body and mind.
- Coronary Stent Market revenue to cross USD 8.7 Bn by 2027: Global Market Insights, Inc.on March 2, 2021 at 4:49 am
Cardiac centers segment in the coronary stent market is estimated to attain a CAGR of 4.6% through 2027 owing to increasing prevalence of coronary artery diseases, reduced cost of post cardiac ...
- Arnulfo Rufo A. Noble Jr.: 2021 candidate for Oakbrook Terrace mayoron March 1, 2021 at 2:49 pm
Two candidates are running for a 4-year term as Oakbrook Terrace mayor. Civic involvement: Since 1987, I have 20 years of leadership experience in various government functions for our city, plus I was ...
- The keyboards of TechCrunch's editorial staffon March 1, 2021 at 1:38 pm
This is a sampling of some of the keyboards used by TechCrunch’s editorial staff. Please note this post is not sponsored and TechCrunch does not earn anything from keyboard sales. Now, should you get ...
- Altai Balance Reviews - Effective Ingredients or Cheap Blood Sugar Pills? 2021 Reviewon February 26, 2021 at 7:07 pm
Altai Balance claims to “reset” your blood sugar, helping people with diabetes restore healthy blood sugar levels and resume living a normal life. Altai Balance Altai Balance claims to “reset” your ...
- How Naps Can Keep You Happy and Healthyon February 25, 2021 at 5:05 am
We nap to care for our souls." And the best news is that not only do naps feel good, but they are (mostly) good for you. "Napping whenever I want to is one of the great pleasures of retirement." The ...
- Healthbeat: Revascularization treatment helps cardiac patient not fit for heart surgeryon February 24, 2021 at 11:04 am
Technology has evolved so greatly in recent decades to give heart patients so much hope. But what happens if you’re too ill to undergo ...
- Australia's antitrust chief claims victory after Facebook standoffon February 24, 2021 at 3:55 am
The architect of Australia's laws forcing Google and Facebook to pay media companies for content claimed victory on Wednesday, though critics said last-minute changes to appease Facebook favoured Big ...
- America is behind bars. Trust will set us freeon February 23, 2021 at 9:08 pm
Americans are losing trust in their institutions, and when that trust is gone, mayhem arises. We see violence. We see attempts to subvert democracy, and we get armed guards patrolling the Capitol.
via Bing News